Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Cyrielle Fougeroux, AdaptVac Aps
  • ,
  • Louise Goksøyr, AdaptVac Aps, University of Copenhagen
  • ,
  • Manja Idorn
  • Vladislav Soroka, Expres 2 ion Biotechnologies Aps
  • ,
  • Sebenzile K. Myeni, Leiden University
  • ,
  • Robert Dagil, University of Copenhagen, VAR2pharmaceuticals
  • ,
  • Christoph M. Janitzek, University of Copenhagen
  • ,
  • Max Søgaard, Expres 2 ion Biotechnologies Aps
  • ,
  • Kara Lee Aves, University of Copenhagen
  • ,
  • Emma W. Horsted, University of Copenhagen
  • ,
  • Sayit Mahmut Erdoğan, University of Copenhagen, Ministry of Health Turkey
  • ,
  • Tobias Gustavsson, University of Copenhagen, VAR2pharmaceuticals
  • ,
  • Jerzy Dorosz, Expres 2 ion Biotechnologies Aps
  • ,
  • Stine Clemmensen, Expres 2 ion Biotechnologies Aps
  • ,
  • Laurits Fredsgaard, University of Copenhagen
  • ,
  • Susan Thrane, AdaptVac Aps
  • ,
  • Elena E. Vidal-Calvo, VAR2pharmaceuticals
  • ,
  • Paul Khalifé, University of Copenhagen
  • ,
  • Thomas M. Hulen, University of Copenhagen
  • ,
  • Swati Choudhary, University of Copenhagen, VAR2pharmaceuticals
  • ,
  • Michael Theisen, University of Copenhagen, Statens Serum Institut
  • ,
  • Susheel K. Singh, University of Copenhagen, Statens Serum Institut
  • ,
  • Asier Garcia-Senosiain, University of Copenhagen, Statens Serum Institut
  • ,
  • Linda Van Oosten, Laboratory of Virology
  • ,
  • Gorben Pijlman, Laboratory of Virology
  • ,
  • Bettina Hierzberger, Expres 2 ion Biotechnologies Aps
  • ,
  • Tanja Domeyer, Expres 2 ion Biotechnologies Aps
  • ,
  • Blanka W. Nalewajek, Expres 2 ion Biotechnologies Aps
  • ,
  • Anette Strøbæk, Expres 2 ion Biotechnologies Aps
  • ,
  • Magdalena Skrzypczak, Expres 2 ion Biotechnologies Aps
  • ,
  • Laura F. Andersson, Expres 2 ion Biotechnologies Aps
  • ,
  • Søren Buus, University of Copenhagen
  • ,
  • Anette Stryhn Buus, University of Copenhagen
  • ,
  • Jan Pravsgaard Christensen, University of Copenhagen
  • ,
  • Tim J. Dalebout, Leiden University
  • ,
  • Kasper Iversen, University of Copenhagen
  • ,
  • Lene H. Harritshøj, University of Copenhagen
  • ,
  • Benjamin Mordmüller, University of Tübingen, Centre de Recherches Médicales de Lambaréné
  • ,
  • Henrik Ullum, University of Copenhagen
  • ,
  • Line S. Reinert
  • Willem Adriaan de Jongh, AdaptVac Aps, Expres 2 ion Biotechnologies Aps
  • ,
  • Marjolein Kikkert, Leiden University
  • ,
  • Søren R. Paludan
  • Thor G. Theander, University of Copenhagen
  • ,
  • Morten A. Nielsen, University of Copenhagen
  • ,
  • Ali Salanti, University of Copenhagen, VAR2pharmaceuticals
  • ,
  • Adam F. Sander, AdaptVac Aps, University of Copenhagen

The rapid development of a SARS-CoV-2 vaccine is a global priority. Here, we develop two capsid-like particle (CLP)-based vaccines displaying the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. RBD antigens are displayed on AP205 CLPs through a split-protein Tag/Catcher, ensuring unidirectional and high-density display of RBD. Both soluble recombinant RBD and RBD displayed on CLPs bind the ACE2 receptor with nanomolar affinity. Mice are vaccinated with soluble RBD or CLP-displayed RBD, formulated in Squalene-Water-Emulsion. The RBD-CLP vaccines induce higher levels of serum anti-spike antibodies than the soluble RBD vaccines. Remarkably, one injection with our lead RBD-CLP vaccine in mice elicits virus neutralization antibody titers comparable to those found in patients that had recovered from COVID-19. Following booster vaccinations, the virus neutralization titers exceed those measured after natural infection, at serum dilutions above 1:10,000. Thus, the RBD-CLP vaccine is a highly promising candidate for preventing COVID-19.

Original languageEnglish
Article number324
JournalNature Communications
Volume12
Issue1
Number of pages11
ISSN2041-1723
DOIs
Publication statusPublished - Jan 2021

See relations at Aarhus University Citationformats

ID: 209765010